再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

REGN 再生元制药公司

未开盘 04-24 16:00:00 EDT

906.54

-0.78

-0.09%

盘后906.88

+0.34+0.04%

19:28 EDT

最高915.70	最低904.41	成交量36.97万
今开906.90	昨收907.32	日振幅1.24%
总市值995.04亿	流通市值951.87亿	总股本1.10亿
成交额3.36亿	换手率0.35%	流通股本1.05亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"再生元制药公司","latestPrice":906.54,"timestamp":1713988800000,"preClose":907.32,"halted":0,"volume":369734,"hourTrading":{"tag":"盘后","latestPrice":906.88,"preClose":906.54,"latestTime":"19:28 EDT","volume":29583,"amount":26819436.96,"timestamp":1714001283103},"delay":0,"floatShares":105000000,"shares":109761896,"eps":34.77,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.78,"latestTime":"04-24 16:00:00 EDT","open":906.9,"high":915.7,"low":904.41,"amount":336237711.64024,"amplitude":0.012443,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":34.77,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1714032000000},"adr":0,"adjPreClose":907.32,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":902.05,"preClose":907.32,"latestTime":"09:27 EDT","volume":171,"amount":154149.41376,"timestamp":1713965270063},"postHourTrading":{"tag":"盘后","latestPrice":906.88,"preClose":906.54,"latestTime":"19:28 EDT","volume":29583,"amount":26819436.96,"timestamp":1714001283103},"volumeRatio":0.872282},"requestUrl":"/m/hq/s/REGN","defaultTab":"news","newsList":[{"id":"2429126921","title":"再生元制药公司涨0.86% 股价突破900美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2429126921","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429126921?lang=zh_cn&edition=full","pubTime":"2024-04-22 21:32","pubTimestamp":1713792748,"startTime":"0","endTime":"0","summary":"北京时间2024年04月22日21时32分，再生元制药公司股票出现波动，股价急速拉升0.86%。截至发稿，该股报904.54美元/股，成交量5042股，换手率0.00%，振幅0.00%。最近的财报数据显示，该股实现营业收入131.17亿美元，净利润39.54亿美元，每股收益37.05美元，毛利108.73亿美元，市盈率26.01倍。再生元制药公司股票所在的生物技术行业中，整体涨幅为0.53%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042221322887a19640&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042221322887a19640&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428528706","title":"再生元制药公司涨2.64% 股价突破900美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2428528706","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428528706?lang=zh_cn&edition=full","pubTime":"2024-04-19 21:31","pubTimestamp":1713533468,"startTime":"0","endTime":"0","summary":"北京时间2024年04月19日21时31分，再生元制药公司股票出现异动，股价急速拉升2.64%。截至发稿，该股报917.58美元/股，成交量3.7379万股，换手率0.03%，振幅0.46%。最近的财报数据显示，该股实现营业收入131.17亿美元，净利润39.54亿美元，每股收益37.05美元，毛利108.73亿美元，市盈率26.39倍。机构评级方面，在所有29家参与评级的机构中，69%的券商给予买入建议，24%的券商给予持有建议，7%的券商给予卖出建议。再生元制药公司股票所在的生物技术行业中，整体涨幅为1.15%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404192131088795f3fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404192131088795f3fc&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427827066","title":"再生元制药公司涨0.22% 股价突破900美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2427827066","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427827066?lang=zh_cn&edition=full","pubTime":"2024-04-16 21:34","pubTimestamp":1713274441,"startTime":"0","endTime":"0","summary":"北京时间2024年04月16日21时34分，再生元制药公司股票出现异动，股价快速拉升0.22%。截至发稿，该股报900.57美元/股，成交量1.0369万股，换手率0.01%，振幅0.33%。最近的财报数据显示，该股实现营业收入131.17亿美元，净利润39.54亿美元，每股收益37.05美元，毛利108.73亿美元，市盈率25.88倍。机构评级方面，在所有28家参与评级的机构中，71%的券商给予买入建议，21%的券商给予持有建议，8%的券商给予卖出建议。再生元制药公司股票所在的生物技术行业中，整体跌幅为0.50%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041621340187e80f85&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041621340187e80f85&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427985521","title":"更新版 1-Regeneron 将就司法部关于药品价格操纵的投诉进行辩护","url":"https://stock-news.laohu8.com/highlight/detail?id=2427985521","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2427985521?lang=zh_cn&edition=full","pubTime":"2024-04-16 07:59","pubTimestamp":1713225561,"startTime":"0","endTime":"0","summary":"     路透社4月15日 - Regeneron Pharmaceuticals   周一表示，该公司寻求对美国司法部指控其虚报黄斑变性药物Eylea平均销售价格的指控进行抗辩。\"Regeneron 在一份声明中说：\"向分销商报销信用卡服务费不是价格优惠，也不会影响 EYLEA 的价格。美国司法部上周在波士顿联邦法院提交的一份诉状中称， ，这家制药商多年来一直没有报告它是如何通过向药品分销商报销信用卡手续费的方式支付数亿美元来补贴Eylea的采购的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2427858710","title":"Regeneron 将为美国司法部关于药物定价操纵的指控进行辩护","url":"https://stock-news.laohu8.com/highlight/detail?id=2427858710","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2427858710?lang=zh_cn&edition=full","pubTime":"2024-04-16 07:20","pubTimestamp":1713223210,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社4月15日 - Regeneron Pharmaceuticals   周一表示，美国司法部对该公司虚报黄斑变性药物Eylea平均销售价格的指控 \"毫无根据\"，该公司计划在法庭上为此案辩护。司法部上周指控 (link) Regeneron 操纵了医疗保险的药品定价程序，夸大了其 Eylea 药物的平均销售价格。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2427881546","title":"再生元制药公司跌0.52% 股价跌破900美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2427881546","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427881546?lang=zh_cn&edition=full","pubTime":"2024-04-16 01:29","pubTimestamp":1713202164,"startTime":"0","endTime":"0","summary":"北京时间2024年04月16日01时29分，再生元制药公司股票出现异动，股价快速下挫0.52%。截至发稿，该股报900.00美元/股，成交量18.3404万股，换手率0.17%，振幅2.32%。最近的财报数据显示，该股实现营业收入131.17亿美元，净利润39.54亿美元，每股收益37.05美元，毛利108.73亿美元，市盈率25.90倍。再生元制药公司股票所在的生物技术行业中，整体跌幅为0.09%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240416012924861e5de5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240416012924861e5de5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427620730","title":"再生元制药公司跌2.21% 股价跌破900美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2427620730","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427620730?lang=zh_cn&edition=full","pubTime":"2024-04-13 00:32","pubTimestamp":1712939565,"startTime":"0","endTime":"0","summary":"北京时间2024年04月13日00时32分，再生元制药公司股票出现波动，股价大幅下挫2.21%。截至发稿，该股报900.00美元/股，成交量19.7375万股，换手率0.18%，振幅1.32%。再生元制药公司股票所在的生物技术行业中，整体跌幅为1.25%。消息层面，截至00时32分，《B of A Securities：维持Regeneron Pharmaceuticals评级，由低于大市调整至低于大市评级, 目标价由710.00美元调整至720.00美元。》资讯为影响再生元制药公司的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240413003245861e55a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240413003245861e55a3&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426078967","title":"B of A Securities：维持Regeneron Pharmaceuticals(REGN.US)评级，由低于大市调整至低于大市评级, 目标价由710.00美元调整至720.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2426078967","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426078967?lang=zh_cn&edition=full","pubTime":"2024-04-12 20:15","pubTimestamp":1712924147,"startTime":"0","endTime":"0","summary":"B of A Securities：维持Regeneron Pharmaceuticals(REGN.US)评级，由低于大市调整至低于大市评级, 目标价由710.00美元调整至720.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404122015528b1701ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404122015528b1701ae&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426762202","title":"美国研究综述-Cheesecake Factory、Netflix、Texas Roadhouse","url":"https://stock-news.laohu8.com/highlight/detail?id=2426762202","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2426762202?lang=zh_cn&edition=full","pubTime":"2024-04-12 15:04","pubTimestamp":1712905476,"startTime":"0","endTime":"0","summary":"    路透社4月12日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括 Cheesecake Factory、Netflix 和 Texas Roadhouse。要闻             * Cheesecake Factory Inc   ：斯蒂芬斯恢复覆盖，给予增持评级             * Netflix Inc   ：Piper Sandler将目标价从550美元上调至600美元             * Texas Roadhouse Inc   ：斯蒂芬斯恢复对该公司的研究，给予等权重评级 以下是路透社周五报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2426319009","title":"加拿大皇家银行：重申Regeneron Pharmaceuticals(REGN.US)评级，由优于大市调整至优于大市评级, 目标价1189.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2426319009","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426319009?lang=zh_cn&edition=full","pubTime":"2024-04-09 21:56","pubTimestamp":1712670971,"startTime":"0","endTime":"0","summary":"加拿大皇家银行：重申Regeneron Pharmaceuticals(REGN.US)评级，由优于大市调整至优于大市评级, 目标价1189.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240409215615875a40da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240409215615875a40da&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422949519","title":"BUZZ-Regeneron 因 FDA 拒绝批准其血癌疗法而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2422949519","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2422949519?lang=zh_cn&edition=full","pubTime":"2024-03-25 20:30","pubTimestamp":1711369819,"startTime":"0","endTime":"0","summary":"    3月25日 - ** 制药公司Regeneron Pharmaceuticals   股价盘前下跌约1.7%，至951美元** 该公司称， ，美国 FDA 拒绝批准其实验性血液癌症疗法 odronextamab 用于两种淋巴瘤的治疗。** 称 CRL 没有发现临床安全性或有效性、试验设计、标签或生产方面的任何问题** 补充说，公司正与 FDA 密切合作，并计划在今年晚些时候分享有关注册和监管时间表的最新信息** 截至上次收盘，公司股价在过去 12 个月中上涨了 18","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2417506347","title":"更新版 1-勃林格下调吸入器自付费用上限为每月 35 美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2417506347","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417506347?lang=zh_cn&edition=full","pubTime":"2024-03-07 20:29","pubTimestamp":1709814548,"startTime":"0","endTime":"0","summary":"     路透社3月7日 - 勃林格殷格翰公司周四表示，从 6 月 1 日起，该公司治疗慢性肺病和哮喘的吸入器产品的自付费用上限为每月 35 美元。勃林格公司还将降低部分吸入器产品的上市价格，但没有提供更多细节。该公司已经降低了其全系列吸入器产品的自付费用，包括用于治疗哮喘和慢性阻塞性肺病等呼吸系统疾病的 Atrovent、Combivent Respimat 和 Spiriva HandiHaler，这是一种常见于吸烟者的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2417756572","title":"勃林格将把吸入器的自付费用降至 35 美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2417756572","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417756572?lang=zh_cn&edition=full","pubTime":"2024-03-07 19:00","pubTimestamp":1709809232,"startTime":"0","endTime":"0","summary":"    路透社3月7日 - 德国制药商勃林格殷格翰公司周四表示，从6月1日起，该公司治疗慢性肺病和哮喘的吸入器产品的自付费用将降至每月35美元。美国高昂的医疗费用是立法者和政治家们严重关切的问题，而降低医疗费用是乔-拜登总统 2024 年竞选连任的关键部分。慢性阻塞性肺病或 \"吸烟者之肺 \"会逐渐损害肺部，据美国疾病控制和预防中心称，约有 1600 万美国人患有这种疾病，它是导致美国人死亡的第六大原因。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2413764215","title":"难治性癌症ORR达71%！再生元制药(REGN.US)双特异性抗体获FDA优先审评资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2413764215","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2413764215?lang=zh_cn&edition=full","pubTime":"2024-02-22 21:43","pubTimestamp":1708609389,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2月22日，再生元制药宣布，美国FDA已接受其靶向B细胞成熟抗原与CD3的双特异性抗体疗法linvoseltamab的生物制品许可申请并授予优先审评资格，用以治疗患有复发/难治性(R/R)多发性骨髓瘤的成年患者，患者在接受至少三种既往疗法后发生疾病进展。据了解，Linvoseltamab是一种旨在将多发性骨髓瘤细胞上的BCMA与表达CD3的T细胞桥接，以促进T细胞活化和癌细胞杀伤的双特异性抗体。最常发生的AE为细胞因子释放综合征。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1075280.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2409458331","title":"眼病疗法中期数据 \"全面达标\"，4D分子公司业绩大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2409458331","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2409458331?lang=zh_cn&edition=full","pubTime":"2024-02-06 01:36","pubTimestamp":1707154582,"startTime":"0","endTime":"0","summary":"沃尔特说，这些数据 \"符合所有条件\"。美国疾病控制和预防中心的数据显示，估计有1980万40岁及以上的美国人患有老年性黄斑变性，其中149万人面临丧失视力的风险。\"4D Molecular公司预计将于2025年第一季度开始晚期试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2408929684","title":"再生元制药公司2023财年实现净利润39.54亿美元，同比减少8.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2408929684","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2408929684?lang=zh_cn&edition=full","pubTime":"2024-02-04 00:23","pubTimestamp":1706977431,"startTime":"0","endTime":"0","summary":"12月31日，再生元制药公司公布财报，公告显示公司2023财年净利润为39.54亿美元，同比减少8.85%；其中营业收入为131.17亿美元，同比增加7.75%，每股基本收益为37.05美元。从资产负债表来看，再生元制药公司总负债71.07亿美元，其中短期债务--，资产负债比为4.66，流动比率为6.42。机构评级：截至2023年12月31日，当前有21家机构对再生元制药公司目标价做出预测，其中目标均价为1003.92美元，其中最低目标价为710.00美元，最高目标价为1135.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024020400235381683058&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024020400235381683058&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2408982252","title":"再生元制药公司公布截至 12 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2408982252","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2408982252?lang=zh_cn&edition=full","pubTime":"2024-02-02 22:30","pubTimestamp":1706884243,"startTime":"0","endTime":"0","summary":"   * Regeneron Pharmaceuticals Inc    公布的截至 12 月的季度调整后每股收益为 11.86 美元，低于去年同期的每股收益 12.56 美元。22位分析师对该季度的平均预期为每股收益10.73美元。华尔街预期为每股收益 7.53 美元至 13.48 美元。* Regeneron Pharmaceuticals Inc公布的本季度每股收益为10.19美元。* 公司报告的季度净收入为 11.6 亿美元。* Regeneron Pharmaceuticals Inc 的股价本季度上涨了 9.1%。华尔街对 Regeneron Pharmaceuticals Inc 的 12 个月目标价中位数为 1,013.50 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2408985897","title":"BUZZ-Regeneron 第四季度盈利超出预期，股价攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=2408985897","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2408985897?lang=zh_cn&edition=full","pubTime":"2024-02-02 21:18","pubTimestamp":1706879883,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    2月2日 - ** Regeneron股价  盘前上涨2.8%至985美元** 制药商第四季度营收超出预期 (link)，因为其大片眼药Eylea的销售额达到了制药商的初步预期目标** 总营收为34.3亿美元，分析师预计为32.9亿美元 - LSEG数据** Eylea 的销售额为 14.6 亿美元，其中包括来自高剂量版本的 1.23 亿美元，符合该公司之前在 1 月份制定的目标。** REGN 第四季度的利润为每小时 11.86 美元，预期为每小时 10.8 美元。** 截至周四收盘，该公司股价在过去 12 个月中上涨了约 26","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2408081601","title":"更新版 1-Regeneron 第四季度收入超出预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2408081601","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2408081601?lang=zh_cn&edition=full","pubTime":"2024-02-02 20:01","pubTimestamp":1706875295,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 )) (第2段增加了Eylea的销售额，第4段增加了FDA申请的细节)    路透2月2日 - Regeneron   周五公布的第四季度营收超出华尔街预期，原因是其大片眼药Eylea的销售额达到了制药商的初步预期目标。Eylea的销售额为14.6亿美元，其中包括来自高剂量版本药物的1.23亿美元，符合该公司此前在1月份制定的目标。根据 LSEG 的数据，总收入为 34.3 亿美元，高于分析师预计的 32.9 亿美元。该公司还表示，已向美国食品和药物管理局提交申请，扩大湿疹治疗药物Dupixent在慢性阻塞性肺病患者中的使用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":0.0059},{"period":"1month","weight":-0.0568},{"period":"3month","weight":-0.0446},{"period":"6month","weight":0.1695},{"period":"1year","weight":0.1481},{"period":"ytd","weight":0.0322}],"compareEarnings":[{"period":"1week","weight":0.0097},{"period":"1month","weight":-0.0276},{"period":"3month","weight":0.0356},{"period":"6month","weight":0.2307},{"period":"1year","weight":0.2446},{"period":"ytd","weight":0.0633}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再生元制药公司于1988年在纽约州成立。再生元制药公司是一家完全集成的生物技术公司，它发现、发明、开发、制造和商业化治疗严重疾病的药物。其正在开发的商业化药物和候选产品旨在帮助患有眼疾、过敏性和炎症性疾病、癌症、心血管和代谢性疾病、疼痛、传染病和罕见疾病的患者。它的核心业务战略是在基础科学研究和发现启用技术方面保持坚实的基础，并建立在临床开发、制造和商业能力的基础上。其目标是继续成为一家综合性、多产品的生物技术公司，为患者和医疗专业人员提供预防和治疗人类疾病的重要选择。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.041845},{"month":2,"riseRate":0.393939,"avgChangeRate":0.089316},{"month":3,"riseRate":0.484848,"avgChangeRate":-0.042863},{"month":4,"riseRate":0.484848,"avgChangeRate":0.019907},{"month":5,"riseRate":0.636364,"avgChangeRate":0.063408},{"month":6,"riseRate":0.393939,"avgChangeRate":0.002817},{"month":7,"riseRate":0.636364,"avgChangeRate":0.053843},{"month":8,"riseRate":0.515152,"avgChangeRate":0.019343},{"month":9,"riseRate":0.484848,"avgChangeRate":0.029068},{"month":10,"riseRate":0.393939,"avgChangeRate":-0.00018},{"month":11,"riseRate":0.545455,"avgChangeRate":0.046018},{"month":12,"riseRate":0.515152,"avgChangeRate":0.048311}],"exchange":"NASDAQ","name":"再生元制药公司","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再生元制药公司,REGN,再生元制药公司股票,再生元制药公司股票老虎,再生元制药公司股票老虎国际,再生元制药公司行情,再生元制药公司股票行情,再生元制药公司股价,再生元制药公司股市,再生元制药公司股票价格,再生元制药公司股票交易,再生元制药公司股票购买,再生元制药公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}